Advisory Resource Group Raises Holdings in Novo Nordisk A/S (NYSE:NVO)

Advisory Resource Group increased its position in Novo Nordisk A/S (NYSE:NVO) by 61.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 11,985 shares of the company’s stock after purchasing an additional 4,544 shares during the period. Advisory Resource Group’s holdings in Novo Nordisk A/S were worth $1,031,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at approximately $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $42,000. Albion Financial Group UT grew its position in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares during the last quarter. Sound Income Strategies LLC increased its stake in Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares during the period. Finally, Hager Investment Management Services LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $46,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $86.39 on Friday. The firm has a market cap of $387.66 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 0.96 and a beta of 0.45. The business’s 50 day moving average is $91.46 and its two-hundred day moving average is $111.51. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 21.88%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NVO. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.